Sugi Predict

Sugi Predict / Compounds / SCHEMBL2895772

SCHEMBL2895772

SCHEMBL2895772

CC1(C)CC2CC(C)(CN2C(=O)c2ccc(NC(=O)CN3CCN(c4ncccn4)CC3)cc2)C1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ DRD2 P14416 1/20 0.49
▸ DRD4 P21917 1/20 0.49
▸ DRD3 P35462 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ AVPR2 P30518 9/20 0.48
▸ AVPR1A P37288 9/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2895059 0.91 THRB (0.57) ALDH1A1KDM4EDRD2DRD4DRD3
SCHEMBL2894949 0.88 ALDH1A1 (0.49) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2893415 0.88 HTT (0.56) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2892452 0.87 ALDH1A1 (0.46) ALDH1A1TDP1KDM4EDRD2DRD4
SCHEMBL2895727 0.86 ALDH1A1 (0.55) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2893651 0.86 ALDH1A1 (0.54) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2895118 0.85 ALDH1A1 (0.56) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2895595 0.85 ALDH1A1 (0.56) ALDH1A1TDP1MEN1HTTKMT2A
SCHEMBL2998722 0.85 DRD4 (0.54) ALDH1A1TDP1DRD2DRD4DRD3
SCHEMBL2895637 0.85 ALDH1A1 (0.53) ALDH1A1TDP1MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-13 — — US claimed
EP-1787982-B1 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS LLC (US) 2010-05-12 — — EP claimed
US-7700583-B2 Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome HIGH POINT PHARMACEUTICALS, LLC (US) 2010-04-20 — — US claimed
EP-1787982-A2 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds Novo Nordisk A/S (DK) 2007-05-23 — — EP claimed
US-20060089349-A1 11beta-hydroxysteroid dehydrogenase type 1 active compounds NOVO NORDISK A/S (DK) 2006-04-27 — — US claimed
EP-1618090-A1 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS NOVO NORDISK A/S (DK) 2006-01-25 — — EP claimed
WO-2004089896-A1 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS NOVO NORDISK A/S (DK) 2004-10-21 — — WO claimed
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-13 — — US disclosed
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-13 — — US disclosed
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-13 — — US disclosed
EP-1787982-B1 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS LLC (US) 2010-05-12 — — EP disclosed
EP-1787982-B1 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS LLC (US) 2010-05-12 — — EP disclosed
US-7700583-B2 Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome HIGH POINT PHARMACEUTICALS, LLC (US) 2010-04-20 — — US disclosed
US-7700583-B2 Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome HIGH POINT PHARMACEUTICALS, LLC (US) 2010-04-20 — — US disclosed
US-7700583-B2 Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome HIGH POINT PHARMACEUTICALS, LLC (US) 2010-04-20 — — US disclosed
WO-2009073460-A2 INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION BAUSCH & LOMB INCORPORATED (US) 2009-06-11 — — WO disclosed
EP-1787982-A2 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds Novo Nordisk A/S (DK) 2007-05-23 — — EP disclosed
EP-1787982-A2 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds Novo Nordisk A/S (DK) 2007-05-23 — — EP disclosed
US-20060089349-A1 11beta-hydroxysteroid dehydrogenase type 1 active compounds NOVO NORDISK A/S (DK) 2006-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120743-A1 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD3B1, HSD17B1 ALDH1A1 59/4885TDP1 1317/4885KDM4E 4334/4885
US-20060089349-A1 11beta-hydroxysteroid dehydrogenase type 1 active compounds HSD11B1, HSD3B1, HSD17B1 ALDH1A1 59/4885TDP1 1317/4885KDM4E 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.